ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,714.07
-0.02%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Sutro Biopharma Inc (STRO)

  7. Sutro Biopharma Inc (STRO) News

Sutro Biopharma (STRO)

Sutro Biopharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:STRO
DateTimeSourceHeadlineSymbolCompany
17/05/202422:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:STROSutro Biopharma Inc
13/05/202421:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
13/05/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
13/05/202421:30GlobeNewswire Inc.Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
30/04/202413:00GlobeNewswire Inc.Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 TrialNASDAQ:STROSutro Biopharma Inc
02/04/202411:18GlobeNewswire Inc.Sutro Biopharma Announces Pricing of $75 Million Underwritten OfferingNASDAQ:STROSutro Biopharma Inc
25/03/202420:30GlobeNewswire Inc.Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
07/03/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
07/03/202421:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
07/03/202421:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
07/03/202421:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
05/03/202421:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
05/03/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
04/03/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
27/02/202421:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:STROSutro Biopharma Inc
13/02/202417:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:STROSutro Biopharma Inc
12/02/202411:06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:STROSutro Biopharma Inc
09/02/202421:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
09/02/202421:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:STROSutro Biopharma Inc
06/02/202421:05GlobeNewswire Inc.Sutro Biopharma to Participate in Upcoming Investor ConferencesNASDAQ:STROSutro Biopharma Inc
31/01/202421:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
29/01/202422:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STROSutro Biopharma Inc
08/01/202412:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
04/01/202421:05GlobeNewswire Inc.Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADCNASDAQ:STROSutro Biopharma Inc
14/12/202321:05GlobeNewswire Inc.Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024NASDAQ:STROSutro Biopharma Inc
11/12/202321:05GlobeNewswire Inc.Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023NASDAQ:STROSutro Biopharma Inc
04/12/202321:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
04/12/202321:05GlobeNewswire Inc.Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:STROSutro Biopharma Inc
27/11/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
27/11/202321:00GlobeNewswire Inc.Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNASDAQ:STROSutro Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:STRO

Your Recent History

BIT
P12AO9
BNP PARIBAS ISSUANCE
TSXV
NOC.H
Norseman Capital
NASDAQ
ABBIPXX
Hsbc Usa Inc Atm Digital...
NYSE
KCJ.L
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved